Palatin Technologies, Inc.今日宣布，其口服MC4R激动剂PL7737在肥胖动物模型中的临床前研究显示积极功效。研究结果表明，PL7737与tirzepatide联用可产生显著的加性减肥效果。效果惊人！口服PL7737在短短4天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药临床试验申请（IND）。这一进展突显了该药物在肥胖治疗领域的潜力，为未来临床试验奠定基础。
Palatin Technologies, Inc.今日宣布，其口服MC4R激动剂PL7737在肥胖动物模型中的临床前研究显示积极功效。研究结果表明，PL7737与tirzepatide联用可产生显著的加性减肥效果。效果惊人！口服PL7737在短短4天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药临床试验申请（IND）。这一进展突显了该药物在肥胖治疗领域的潜力，为未来临床试验奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.